195 related articles for article (PubMed ID: 36892817)
1. Prebiotics targeting gut-liver axis to treat non-alcoholic fatty liver disease.
Castelnuovo G; Perez-Diaz-Del-Campo N; Guariglia M; Poggiolini I; Armandi A; Rosso C; Caviglia GP; Bugianesi E
Minerva Gastroenterol (Torino); 2023 Mar; ():. PubMed ID: 36892817
[TBL] [Abstract][Full Text] [Related]
2. Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations.
Long C; Zhou X; Xia F; Zhou B
Biology (Basel); 2024 Apr; 13(4):. PubMed ID: 38666855
[TBL] [Abstract][Full Text] [Related]
3. Contribution of the gut microbiota to the regulation of host metabolism and energy balance: a focus on the gut-liver axis.
Delzenne NM; Knudsen C; Beaumont M; Rodriguez J; Neyrinck AM; Bindels LB
Proc Nutr Soc; 2019 Aug; 78(3):319-328. PubMed ID: 30628563
[TBL] [Abstract][Full Text] [Related]
4. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.
Kirpich IA; Marsano LS; McClain CJ
Clin Biochem; 2015 Sep; 48(13-14):923-30. PubMed ID: 26151226
[TBL] [Abstract][Full Text] [Related]
5. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
[TBL] [Abstract][Full Text] [Related]
6. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
[TBL] [Abstract][Full Text] [Related]
7. The Gut Microbiota and Its Metabolites, Novel Targets for Treating and Preventing Non-Alcoholic Fatty Liver Disease.
Ni Y; Ni L; Zhuge F; Fu Z
Mol Nutr Food Res; 2020 Sep; 64(17):e2000375. PubMed ID: 32738185
[TBL] [Abstract][Full Text] [Related]
8. Partially hydrolyzed guar gum attenuates non-alcoholic fatty liver disease in mice through the gut-liver axis.
Takayama S; Katada K; Takagi T; Iida T; Ueda T; Mizushima K; Higashimura Y; Morita M; Okayama T; Kamada K; Uchiyama K; Handa O; Ishikawa T; Yasukawa Z; Okubo T; Itoh Y; Naito Y
World J Gastroenterol; 2021 May; 27(18):2160-2176. PubMed ID: 34025071
[TBL] [Abstract][Full Text] [Related]
9. Periodontal treatment and microbiome-targeted therapy in management of periodontitis-related nonalcoholic fatty liver disease with oral and gut dysbiosis.
Kuraji R; Shiba T; Dong TS; Numabe Y; Kapila YL
World J Gastroenterol; 2023 Feb; 29(6):967-996. PubMed ID: 36844143
[TBL] [Abstract][Full Text] [Related]
10. The Role of Gut-Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC.
Song Q; Zhang X
Biomedicines; 2022 Feb; 10(3):. PubMed ID: 35327326
[TBL] [Abstract][Full Text] [Related]
11. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.
Miura K; Ohnishi H
World J Gastroenterol; 2014 Jun; 20(23):7381-91. PubMed ID: 24966608
[TBL] [Abstract][Full Text] [Related]
12. Microbiota Dysbiosis and Gut Barrier Dysfunction Associated with Non-Alcoholic Fatty Liver Disease Are Modulated by a Specific Metabolic Cofactors' Combination.
Quesada-Vázquez S; Bone C; Saha S; Triguero I; Colom-Pellicer M; Aragonès G; Hildebrand F; Del Bas JM; Caimari A; Beraza N; Escoté X
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430154
[TBL] [Abstract][Full Text] [Related]
13. Effect of Microbiome on Non-Alcoholic Fatty Liver Disease and the Role of Probiotics, Prebiotics, and Biogenics.
Nagashimada M; Honda M
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360773
[TBL] [Abstract][Full Text] [Related]
14. The Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review.
Carpi RZ; Barbalho SM; Sloan KP; Laurindo LF; Gonzaga HF; Grippa PC; Zutin TLM; Girio RJS; Repetti CSF; Detregiachi CRP; Bueno PCS; Mazuqueli Pereira ESB; Goulart RA; Haber JFDS
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955942
[TBL] [Abstract][Full Text] [Related]
15. Can You Trust Your Gut? Implicating a Disrupted Intestinal Microbiome in the Progression of NAFLD/NASH.
Jadhav K; Cohen TS
Front Endocrinol (Lausanne); 2020; 11():592157. PubMed ID: 33193105
[TBL] [Abstract][Full Text] [Related]
16. Intestinal microbiota and nonalcoholic steatohepatitis.
Brandl K; Schnabl B
Curr Opin Gastroenterol; 2017 May; 33(3):128-133. PubMed ID: 28257306
[TBL] [Abstract][Full Text] [Related]
17. Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy.
Fianchi F; Liguori A; Gasbarrini A; Grieco A; Miele L
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204274
[TBL] [Abstract][Full Text] [Related]
18. Oral and Gut Microbial Dysbiosis and Non-alcoholic Fatty Liver Disease: The Central Role of
Wang T; Ishikawa T; Sasaki M; Chiba T
Front Med (Lausanne); 2022; 9():822190. PubMed ID: 35308549
[TBL] [Abstract][Full Text] [Related]
19. Fructose: A Dietary Sugar in Crosstalk with Microbiota Contributing to the Development and Progression of Non-Alcoholic Liver Disease.
Lambertz J; Weiskirchen S; Landert S; Weiskirchen R
Front Immunol; 2017; 8():1159. PubMed ID: 28970836
[TBL] [Abstract][Full Text] [Related]
20. Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota?
Li DY; Yang M; Edwards S; Ye SQ
JPEN J Parenter Enteral Nutr; 2013 Nov; 37(6):787-93. PubMed ID: 23538296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
